Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds William Blair Downgrades Actinium Pharmaceuticals to Market Perform

William Blair Downgrades Actinium Pharmaceuticals to Market Perform

William Blair analyst Andy Hsieh downgrades Actinium Pharmaceuticals (AMEX:ATNM) from Outperform to Market Perform.

byBenzinga Newsdesk

February 21, 2023

1 minute read

William Blair analyst Andy Hsieh downgrades Actinium Pharmaceuticals (AMEX:ATNM) from Outperform to Market Perform.

SVB Leerink Maintains Outperform on argenx, Raises Price Target to $428

By Benzinga Newsdesk

July 29, 4:51 AM

SVB Leerink analyst Thomas Smith maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $404 to $428.

ARGX

$1000 Invested In Archer-Daniels Midland 20 Years Ago Would Be Worth This Much Today

By Benzinga Insights

August 16, 11:30 AM

Archer-Daniels Midland (NYSE:ADM) has outperformed the market over the past 20 years by 1.82% on an annualized basis…

ADM

Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate – A Setback in High-Risk Melanoma Treatment

By Vandana Singh

May 13, 11:09 AM

Merck halts vibostolimab and pembrolizumab coformulation arm in KeyVibe-010 Phase 3 trial for high-risk melanoma due to higher discontinuation rates and immune-related adverse events.

MRK

Tesla’s Board Is Desperately Trying To Focus Elon Musk’s Attention On The Company

By Bibhu Pattnaik

May 18, 5:01 PM

The board of Tesla Inc. (NASDAQ: TSLA) is struggling to maintain CEO Elon Musk's total commitment while he manages multiple ventures.

TSLA

William Blair Downgrades Actinium Pharmaceuticals to Market Perform

Related Posts

SVB Leerink Maintains Outperform on argenx, Raises Price Target to $428

$1000 Invested In Archer-Daniels Midland 20 Years Ago Would Be Worth This Much Today

Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate – A Setback in High-Risk Melanoma Treatment

Tesla’s Board Is Desperately Trying To Focus Elon Musk’s Attention On The Company